Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCDR | ISIN: US20451W1018 | Ticker-Symbol: 5Y6
Tradegate
17.05.24
18:14 Uhr
7,300 Euro
+0,050
+0,69 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
COMPASS PATHWAYS PLC ADR Chart 1 Jahr
5-Tage-Chart
COMPASS PATHWAYS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
7,2007,35019:04
7,1507,30017.05.

Aktuelle News zur COMPASS PATHWAYS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoEarnings call: COMPASS Pathways reports progress on COMP360 treatment3
MoCOMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript2
08.05.Compass Pathways gains on mid-stage data for experimental PTSD treatment4
08.05.COMPASS Pathways ADS GAAP EPS of -$0.55 misses by $0.072
08.05.Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights192COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces...
► Artikel lesen
08.05.COMPASS Pathways plc - 10-Q, Quarterly Report2
08.05.Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder180Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5...
► Artikel lesen
08.05.COMPASS Pathways plc - 8-K, Current Report2
03.05.Compass Pathways to announce first quarter financial results on May 8, 20242
02.05.Compass Pathways; Mindful Health Solutions: Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment247LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health...
► Artikel lesen
29.04.Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression265LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health...
► Artikel lesen
01.04.Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference14
28.03.Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors303David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New ChairLONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology...
► Artikel lesen
28.03.COMPASS Pathways plc - 8-K, Current Report9
15.03.Compass Pathways director sells over $700k in company stock9
15.03.Compass Pathways director sells over $700k in company shares13
01.03.Earnings call: COMPASS Pathways reports progress despite trial delays13
29.02.Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment8
29.02.Compass Pathways PLC reports results for the quarter ended in December - Earnings Summary16
29.02.COMPASS Pathways ADS GAAP EPS of -$0.53 misses by $0.177
Seite:  Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3